RACHELLE DOODY to alpha-Synuclein
This is a "connection" page, showing publications RACHELLE DOODY has written about alpha-Synuclein.
Connection Strength
0.245
-
Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
Score: 0.190
-
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
Score: 0.055